Christine E. Hill-Kayser, MD

Radiation Oncology
Accepting new patients
Sees patients age 18 and up
Penn Radiation Oncology Perelman-Concourse Level
Headshot of Christine E. Hill-Kayser, MD
Penn Medicine Provider

About me

  • Chief, Pediatrics Service, Radiation Oncology
  • Professor of Radiation Oncology at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Albert Einstein Medical Center
  • Residency: University of Pennsylvania Health System

Spoken languages

English
English

Reviews

Average Rating

41 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
January 2026
dr. hill-kayser was very knowledgeable and thoughtful, and took the time to provide us with valuable information and answer all our questions.
Anonymous
January 2025
she was kind and answered all our questions.
Anonymous
July 2024
first time visit. not enough experience to recommend.
Anonymous
May 2024
pleasant

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Hill-Kayser is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Kari Bjornard, Allison Close, Leslie Appiah, Sujith Baliga, Brooke Cherven, Veronica Gomez-Lobo, Daniel Green, Christine Hill, Kirsi Jahnukainen, Yasmin Jayasinghe, Jennifer Levine, Brinda Mehta, Rod Mitchell, Molly Moravek, Kyle Orwig, Lillian Meacham, Karen Burns Standardizing Risk Assessment for Treatment-Related Gonadal Insufficiency and Infertility in Childhood, Adolescent and Young Adult Cancer Patients: Updates to the Oncofertility Consortium’s Pediatric and Adolescent Committee Risk Stratification System , 9th World Congress of the International Society for Fertility, Miami, Florida: 2026


Lauren Linkowski, Michelle Iocolano, Seiichi Villalona, Sriya Potluri, Christina Bach, Karen Arnold-Korzeniowski, James Metz, Christine Hill-Kayser Predictors and Equity of Distribution of Educational Materials to Patients Receiving Radiation Therapy for Thoracic Malignancies , American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, Boston, Massachusetts: 2026


Christine Hill-Kayser, Katherine Camberari, Katherine Okonak, Karen Arnold-Korzeinowski, Michelle Iocolano, Andrew Bauer, Dava Szalda, Lisa Schwartz, James Metz, Sogol Mostoufi-Moab Design and Implementation of Survivorship Care Plans for Adolescents and Young Adults Diagnosed with Thyroid Malignancies , American Society for Therapeutic Radiation Oncology (ASTRO) 2016 Annual Meeting, Boston, Massachusetts: 2026


Steve Braunstein, John Lucas, Joseph Panoff, Arlene Naranjo, Kathryn Karolczuk, Emily Greengard, Yael Mosse, Wendy Fitzgerald, Katherine Matthay, Meaghan Granger, Michael Hogarty, Meredith Irwin, Fan Zhang, Brian Weiss, Julie Park, Gregory Yanik, Rochelle Bagatell, Steven Dubois, Christine Hill-Kayser A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Lorlatinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (ANBL1531) , American Society for Therapeutic Radiation Oncology (ASTRO) 2026 Annual Meeting, Boston, Massachusetts: 2026


J.T. Lucas Jr., M.K. Krasin, C. Hill-Kayser, J. Piao, J. Jarzembowski, J. Pogoriler, D. Olson, R. Guillerman, C. Chen, A. Rangaswami, J. Rosenblum, P. Schoettler, J. Kamihara, E. Christison-Lagay, K. Maxa, A. Flynn, A. Ross, W. Pendleton, D. Koach, T. Laetsch, Kris Ann Schultz. Prospective Treatment of Types I, II, & III Pleuropulmonary Blastoma (PPB): A COG Phase 3 Study (ARAR2331) , American Society for Radiation Oncology (ASTRO) Annual Meeting, Boston, Massachusetts: 2026


Ahmed . . Laack Stereotactic Body Radiation Therapy (SBRT) and Comprehensive Metastasis-Directed Therapy for Ewing Sarcoma Patients Enrolled on AEWS1221: A Report from the Children's Oncology Group (COG) , American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, Boston, Massachusetts: 2026


Boulter AC, Weber KL, Huynh MH, Steele J, Mattei P, Hill-Kayser CE, Godlewski K, Crane JN Paraneoplastic Inflammatory Syndrome as the Sole Presenting Symptom of Angiomatoid Fibrous Histiocytoma in a Pediatric Patient , Pediatr Blood Cancer: 2026


Peterson LL, McDonough AL, Ansbaugh SM, Ariza-Heredia EJ, Armenian S, Baker KS, Ballinger TJ, Cathcart-Rake EJ, Cohen SH, Day AT, Evgeniou E, Fairman NP, Feliciano J, Flores TF, Friedman DL, Gabel NM, Hill-Kayser CE, Hock K, Kline-Quiroz C, Lee NK, Mooney K, Moore HCF, Moryl N, Neuman H, Overholser L, Patel CG, Porpiglia A, Rogers LQ, Saidain A, Schapira L, Smith SK, Tenner L, Von Ah D, Yang EH, Zee P, Freedman-Cass D, McMillian N NCCN Guidelines® Insights: Survivorship, Version 3.2026 , J Natl Compr Canc Netw: 2026


Gallitto M, Zhang H, Iandoli M, Fitzgerald TJ, Kalapurakal JA, Krasin MJ, Haas-Kogan DA, Paulino AC, Laack NNI, Wolden SL, Hoppe BS, Hill-Kayser CE, Mahajan A, Yock TI The Evolution of Radiotherapy in Children's Oncology Group Trials, from 1998-2025 , Int J Radiat Oncol Biol Phys: 2026


Alaei P, Mihalcik S, Baliga S, Kwok Y, Casey D, Ehler E, Burton C, Breneman JC, Haas-Kogan DA, Wolden SL, Paulino AC, Laack NN, Esiashvili N, Milgrom S, Hill-Kayser C, Fitzgerald TJ, Kalapurakal JA, Hua CH Guidelines for Pediatric Radiotherapy Simulation: A Report From the Children's Oncology Group Radiation Oncology Discipline , Pediatr Blood Cancer: 2026